Search the Newsreel

Endeavour Silver (NYSE: EXK) sets US$25M revolver, expandable to US$100M

Endeavour Silver Corp. (NYSE: EXK) has secured a US$25 million revolving term credit facility with ING Capital LLC, which can be expanded to US$100 million. This facility, maturing on August 5, 2029, is intended to provide financial flexibility for general corporate and working capital …

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

IDEAYA Biosciences recently reported a wider Q2 2026 net loss of US$112.45 million, or US$1.22 per share, and an overall wider six-month loss compared to the previous year. Despite this, the company is advancing its precision oncology pipeline, initiating a monotherapy expansion for IDE892 …

IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial

Endeavour Silver (NYSE:EXK) Shares Gap Up - Still a Buy?

Endeavour Silver (NYSE:EXK) shares gapped up by 7.6% to $8.96, with nearly 1.9 million shares traded. The company met quarterly earnings expectations with $0.15 EPS and slightly exceeded revenue forecasts at $212.1 million. Analyst sentiment is mixed but generally positive, with a "Moderate Buy" …

Endeavour Silver Corp. Announces USD 25 Million Revolving Term Credit Facility

Endeavour Silver Corp. has secured a new secured revolving term credit facility for up to $25 million with ING Capital LLC. This facility is intended to provide financial flexibility for general corporate and working capital purposes, including potential acquisitions and investments. Although the company …

How Investors Are Reacting To Easterly Government Properties (DEA) Higher Guidance Amid Weaker Earnings

Easterly Government Properties reported mixed Q2 2026 results with higher sales and revenue but lower net income and EPS. Despite weaker earnings, the company raised its full-year guidance and secured a new loan to support its acquisition pipeline, maintaining its dividend. Investors are weighing …

IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary

IDEAYA Biosciences reported its second-quarter 2026 results, showing collaboration revenue of $8.86 million and a net loss of $(112.45) million, or $(1.22) diluted EPS, due to increased R&D and commercial preparation. The company highlighted positive Phase 2/3 clinical trial results for darovasertib, with an …

Endeavour Silver Reports 149% Revenue Surge in Q2 2026

Silver Producers Revenue Jumps 149% as Mine Cash Flow Surges 336%

Endeavour Silver Corp. reported a significant increase in Q2 2026 revenue by 149% to US$212.1 million and a 336% surge in mine operating cash flow before taxes to US$99.9 million. The company's silver production rose by 31%, with total silver equivalent production reaching 3.4 …

Why Endeavour Silver (TSX:EDR) Is Up 7.1% After Swinging Back To Profitability – And What's Next

IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37

Leerink Partners has decreased its target price for IDEAYA Biosciences, Inc. (IDYA.O) from $37 to $31. This adjustment was reported by Reuters on August 5, 2026, at 12:21 PM. The article provides this key financial action without further elaborating on the reasons behind the …

Endeavour Silver Stock Surges as Strong Earnings, Silver Momentum and Terronera Growth Fuel Bullish Pressure

Endeavour Silver establishes $25M credit line as Pitarrilla advances

Endeavour Group (ASX:EDV) Drops as Profit Concerns Shake the Retail Giant

IDEAYA Biosciences (IDYA) Stock Faces Loss Pressure Despite Revenue Traction

IDEAYA Biosciences (IDYA) stock saw a modest increase after its Q2 2026 earnings report, which highlighted significant revenue growth but also widening net losses. While the company achieved substantial revenue traction and secured new funding, its increasing cash burn and lack of a clear …

IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend

IDEAYA Biosciences reported Q2 2026 collaboration revenue of $8.9 million and a net loss of $112.5 million, with R&D expenses significantly increasing to $108.7 million for the quarter. The company strengthened its liquidity through a June 2026 follow-on offering and at-the-market sales, boosting cash, …

Uveal melanoma trial reports 6.9 months progression-free vs. 3.1

IDEAYA Biosciences (IDYA) announced positive results from its registrational Phase 2/3 OptimUM-02 trial for darovasertib plus crizotinib in metastatic uveal melanoma, meeting its primary endpoint with a median progression-free survival (PFS) of 6.9 months compared to 3.1 months for the investigator's choice arm. The …

Long Shortz with Audeara: Turning revenue up, breaking wholesale records and break-even in sight

Ideal Power Inc (IPWR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Ideal Power Inc (IPWR), detailing its current earnings forecast score, price target, and analyst ratings. Based on one analyst, the company has a "Buy" rating with a target price of $10.75, representing a 151.76% upside. The article …

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

IDEAYA Posts Q2 Loss as Cash Reaches $1.24 Billion

IDEAYA Biosciences (IDYA) reported a Q2 2026 net loss of $112.5 million ($1.22 per share) on collaboration revenue of $8.9 million, up from the prior quarter. The company announced its cash, cash equivalents, and marketable securities reached $1.24 billion, with cash runway guidance into …

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences announced its second-quarter 2026 financial results and provided a business update. The company's registrational OptimUM-02 trial for darovasertib combination in metastatic uveal melanoma met its primary endpoint, with an NDA filing underway. IDEAYA also reported a strong financial position with approximately $1.24 …

IDEAYA Biosciences reports Q2 2026 net loss $112.5M; cash $1.24B after $323M offering

IDEAYA Biosciences reported a net loss of $112.5 million for Q2 2026, ending the period with $1.24 billion in cash, cash equivalents, and marketable securities after a $323 million public offering. The company's OptimUM-02 trial met its primary endpoint, leading to an NDA filing …

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

IDEAYA Biosciences (IDYA) reported a wider loss of $1.22 per diluted share in Q2, compared to the previous quarter. Despite the increased loss, the company experienced a rise in revenue during the same period. This article provides a brief overview of IDEAYA's Q2 financial …

Ideal Power (NASDAQ:IPWR) Share Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Ideal Power (NASDAQ:IPWR) shares have fallen below their 200-day moving average, trading at $3.87 compared to the average of $4.37. Analyst sentiment is mixed, with a "Hold" consensus and an average price target of $10.75, despite the company missing quarterly earnings expectations. Institutional investors …

Endeavour Silver (TSE:EDR) Stock Rating Upgraded by B. Riley Financial

ideaForge Technology Q1 Results: Earnings call scheduled for Aug 11

Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M

IDEAYA Biosciences, Inc. (IDYA) announced its Q2 revenue of $8.9 million, surpassing FactSet's estimate of $8.0 million. This news comes alongside other recent updates for the company, including Wedbush adjusting its price target to $60 and maintaining an Outperform rating, and the company's Q2 …

Total Voting Rights

Endeavour Mining PLC TOTAL VOTING RIGHTS London, 3 August 2026 – Endeavour Mining Plc (LEI: 529900NI5MXQ91GHXR07, LSE: EDV, TSX:EDV) ("the Company") The following notification is made in accordance with the UK Financial Conduct Authority's ("FCA's") Disclosure Guidance and Transparency Rule 5.6. As at close …

Easterly Government Properties (DEA) Beats Q2 2026 EPS Target by 0.0%

Easterly Government Properties (DEA) significantly outperformed in Q2 2026, with Core FFO per share of $0.78 and revenue of $92.4 million, marking a 9.7% increase year-over-year. Despite the strong results, the stock declined by 1.4%, suggesting investors might be taking profits or reacting to …

Dimensional Fund Advisors LP Increases Position in IDEAYA Biosciences, Inc. $IDYA

Dimensional Fund Advisors LP significantly increased its stake in IDEAYA Biosciences, Inc. (IDYA) by 42% in Q1, now holding 1.33 million shares valued at $44.4 million. Other institutional investors like State Street and Janus Henderson also boosted their positions, with institutional ownership reaching 98.29%. …

Endeavour tipped for upside as Jefferies pitches bullish target for the gold miner

Endeavour tipped for upside as Jefferies pitches bullish target for the gold miner Proactive uses images sourced from Shutterstock Endeavour Mining PLC (LSE:EDV, TSX:EDV, OTCQX:EDVMF, FRA:6E2) comes out on top as analysts at Jefferies ran the ruler over a number of London-listed gold producers. …

Easterly Government Properties Raises 2026 Guidance After Strong Second-Quarter Performance

Easterly Government Properties (NYSE: DEA) reported strong second-quarter 2026 financial results, leading the company to raise its full-year 2026 Core FFO guidance to a range of $3.07 to $3.13 per diluted share. This performance was driven by new financing activity, including a new $200 …

(DEA) Easterly Government Properties Expects 2026 Core FFO a Share Range $3.07 - $3.13, vs. FactSet Est of $3.10

Easterly Government Properties (DEA) anticipates its 2026 Core FFO (Funds From Operations) per share to be in the range of $3.07 to $3.13. This forecast aligns closely with FactSet's estimated $3.10 per share. The company recently reported its Q2 revenue at $92.4 million and …

IDEAYA Biosciences (IDYA) Expected to Post Earnings on Monday

Endeavour Mining Reports 241.6M Shares for FCA Interest Notices